Clinical Trials Directory

Trials / Completed

CompletedNCT03451032

Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV

Status
Completed
Phase
Study type
Observational
Enrollment
150 (actual)
Sponsor
Nantes University Hospital · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

Prospective, multicenter study to evaluate tolerability, adherence and efficacy of a 28-day course of TAF/FTC/RPV, an HIV post-exposure prophylaxis after a potential sexual or blood exposure to HIV. At baseline, participants are prescribed TAF/FTC/RPV and a blood test. At W6, all participants are contacted by phone to evaluate completeness and tolerability of the TAF/FTC/RPV regimen.

Detailed description

At baseline, participants seek care in one of the centers of " Pays de la Loire " area after a potential HIV exposure. They receive TAF/FTC/RPV, one pill taken with food once daily for 28 days according to national guidelines. They have to start this post-exposure prophylaxis within 48 hours after the HIV exposure. At inclusion, participants give their written consent to have their data recorded in an electronic medical record Nadis® and their oral consent after reading the study information letter. A blood test is prescribed to examine biological variables (HIV, HBV, HCV serologies, TPHA VDRL, ALT/AST, hemogram and serum creatinine). Characteristics of participants and context of the risk are collected in the electronic medical record Nadis®. A blood test is prescribed at W2, W6 and W12 to evaluate tolerability and efficacy of the treatment. At W6, all participants are contacted by phone call to evaluate completeness and tolerability of the TAF/FTC/RPV regimen. They are reminded to have a blood test done at W6 and W12.

Conditions

Interventions

TypeNameDescription
OTHERNon Interventional StudyNon Interventional Study

Timeline

Start date
2018-03-15
Primary completion
2019-03-15
Completion
2019-03-15
First posted
2018-03-01
Last updated
2019-08-28

Locations

6 sites across 1 country: France

Source: ClinicalTrials.gov record NCT03451032. Inclusion in this directory is not an endorsement.